Leveraging Adeno-Associated Viruses (AAVs) in therapeutic approaches for monogenic neurological diseases
Supplied by PerkinElmer on Wednesday, 07 September, 2022
Within the field of neurological diseases, there is great interest in looking at rare diseases of monogenic origin with the hope of developing disease-modifying gene therapies, as opposed to treatments for symptom management. Therefore, using relatively tunable systems like recombinant AAVs, scientists are also exploring in vivo gene delivery in parallel to ex vivo.
Learn about key strategies and innovations in this space that are enabling advanced gene therapy.
Related White Papers
Limit your risk, avoid waste and ensure compliance to government legislation
This paper provides an overview of the importance...
How to re-socialise your workplace post COVID-19
Learn how to reimagine your workspace, take full advantage of workplace socialisation and...
Digital innovation drives smarter, faster biologics development
[Case study] From bottleneck to breakthroughs: a...
